Synergistic associations of catechol-O-methyltransferase and brain-derived neurotrophic factor with executive function in agingare selective and modified by apolipoprotein E

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 249-256

  Sapkota, Shraddha ^a   Vergote, David ^b   Westaway, David ^a,b   Jhamandas, Jack ^a   Dixon, Roger A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aging; Apolipoprotein E; Brain derived neurotrophic factor; Catechol O methyltransferase; Executive function; Victoria longitudinal study

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; COMT PROTEIN, HUMAN;

ADULT; AGED; AGING; ALLELE; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; EXECUTIVE FUNCTION; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RECOMBINATION; GENETIC RISK; HUMAN; MALE; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; EPISTASIS; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PHYSIOLOGY; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; APOLIPOPROTEINS E; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; EPISTASIS, GENETIC; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK;

EID: 84920582793     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.06.020     Document Type: Article

References (66)

1. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
2. Altmann A., Tian L., Henderson V.W., Greicius M.D. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann. Neurol. 2014, 75:563-573. Alzheimer's Disease Neuroimaging Initiative Investigators.
3. Anstey K.J. Cognitive aging and functional biomarkers: what do we know, and where to from here?. Handbook of Cognitive Aging: Interdisciplinary Perspectives 2008, 327-339. Sage, Thousand Oaks, CA. S.M. Hofer, D.F. Alwin (Eds.).
4. Bäckman L., Lindenberger U., Li S., Nyberg L. Linking cognitive aging to alterations in dopamine neurotransmitter functioning: recent data and future avenues. Neurosci. Biobehav. Rev. 2006, 34:670-677.
5. Bellander M., Brehmer Y., Westerberg H., Karlsson S., Furth D., Bergman O., Eriksson E., Bäckman L. Preliminary evidence that allelic variation in the LMX1A gene influences training-related working memory improvement. Neuropsychologia 2011, 49:1938-1942.
6. Belsky J., Jonassaint C., Pluess M., Stanton M., Brummett B., Williams R. Vulnerability genes or plasticity genes. Mol. Psychiatry 2009, 14:746-754.
7. Bertolino A., Blasi G., Latorre V., Rubino V., Rampino A., Sinibaldi L., Caforio G., Petruzzella V., Pizzuti A., Scarabino T., Nardini M., Weinberger D.R., Dallapiccola B. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J.Neurosci. 2006, 26:3918-3922.
8. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neurpsychopharmacology 2004, 29:1943-1961.
9. Brainerd C.J., Reyna V.F., Petersen R.C., Smith G.E., Taub E.S. Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative sample. Neuropsychology 2011, 25:679-689.
10. Canli T., Congdon E., Constable R.T., Lesch K.P. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing. Biol. Psychol. 2008, 79:118-125.
11. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
12. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmier J.B., Locke P.A., Connearlly P.M., Schmader K.E., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
13. Deary I.J., Wright A.F., Harris S.E., Whalley L.J., Starr J.M. Searching for genetic influences on normal cognitive ageing. Trends Cogn. Sci. 2004, 8:178-184.
14. de-Almada B.V., de-Almeida L.D., Camporez D., de-Moraes M.V., Morelato R.L., Perrone A.M., Belcavello L., Louro I.D., de-Paula F. Protective effect of the APOE-e3 allele in Alzheimer's disease. Braz. J. Med. Biol. Res. 2011, 45:8-12.
15. de Frias C.M., Dixon R.A., Strauss E. Structure of four executive functioning tests in healthy older adults. Neuropsychology 2006, 20:206-214.
16. de Frias C.M., Dixon R.A., Strauss E. Characterizing executive functions in older special populations: from cognitively elite to cognitively impaired. Neuropsychology 2009, 23:778-791.
17. Deshmukh A., Rodrigue K.M., Kennedy K.M., Land S., Jacobs B.S., Raz N. Synergistic effects of the MTHFR C677T polymorphism and hypertension on spatial navigation. Biol. Psychol. 2009, 80:240-245.
18. Dixon, R.A., DeCarlo, C.A., MacDonald, S.W.S., Vergote, D., Jhamandas, J., Westaway, D., 2014. APOE and COMT polymorphisms are complementary markers of status and stability in normal aging and mild cognitive impairment. Unpublished results.
19. Dixon R.A., de Frias C.M. Victoria Longitudinal Study: from cognitive aging to illustrating changes in memory compensation. Aging Neuropsychol. C 2004, 11:346-376.
20. Dolcos S., MacDonald S.W.S., Braslavsky A., Camicioli R., Dixon R.A. Mild cognitive impairment is associated with selected functional markers: integrating concurrent, longitudinal, and stability effects. Neuropsychology 2012, 26:209-233.
21. Edland S.D., Wavrant-De Vriese F., Compton D., Smith G.E., Ivnik R., Boeve B.F., Tangalos E.G., Peterson R.C. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci. Lett. 2003, 345:21-24.
22. Elias-Sonnenschein L.S., Viechtbauer W., Ramakers I.H., Verhey F.R., Visser P.J. Predictive value of the APOE-epsilon4 allele for progression from MCI to AD-type dementia: a meta-analysis. J.Neurol. Neurosurg. Psychiatry 2011, 82:1149-1156.
23. Erickson K.I., Kim J.S., Suever B.L., Voss M.W., Francis B.M., Kramer A.F. Genetic contributions to age-related decline in executive function: a 10-year longitudinal study of COMT and BDNF polymorphisms. Front. Hum. Neurosci. 2008, 2:1-9.
24. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT val108/158 met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U.S.A 2001, 98:6917-6922.
25. Farlow M.R., He Y., Tekin S., Xu J., Lane R., Charles H.C. Impact of APOE in mild cognitive impairment. Neurology 2004, 63:1898-1901.
26. Fotuhi M., Hachinski V., Whitehouse P.J. Changing perspectives regarding late-life dementia. Nat. Rev. Neurol. 2009, 5:649-658.
27. Goldberg T.E., Weinberger D.R. Genes and the parsing of cognitive processes. Trends Cogn. Sci. 2004, 8:325-335.
28. Gomar J.J., Bobes-Bascaran M.T., Conejero-Goldberg C., Davies P., Goldberg T.E. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch. Gen. Psychiatry 2011, 68:961-969.
29. Green A.E., Munafo M.R., DeYoung C.G., Fossella J.A., Fan J., Gray J.R. Using genetic data in cognitive neuroscience: from growing pains to genuine insights. Nat. Rev. Neurosci. 2008, 9:710-720.
30. Harris, S.E., Davies, G., Luciano, M., Payton, A., Fox, H.C., Haggarty, P., Horan, O.W., Porteous, D.J., Starr, J.M., Whalley, L.J., Pendleton, N., Deary, I.J., in press. Polygenic risk for Alzheimer's disease is not associated with cognitive ability or cognitive aging in non-demented older people. J. Alzheimers Dis.
31. Harris S.E., Deary I.J. The genetics of cognitive ability and cognitive ageing in healthy older people. Trends Cogn. Sci. 2011, 15:388-394.
32. Henderson A.S., Jorm A.F., Korten A.E., Christensen H., Jacomb P.A., Easteal S., Croft L., Mackinnon A.J. Apolipoprotein E allele ε4, dementia, and cognitive decline in a population sample. Lancet 1995, 346:1387-1390.
33. Jochemsen H.M., Muller M., van der Graaf Y., Geerlings M.I. APOE ε4 differentially influences change in memory performance depending on age. The SMART-MR study. Neurobiol. Aging 2012, 33:832.e15-832.e22.
34. Kang J.H., Logroscino G., De Vivo I., Hunter D., Grodstein F. Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiol. Aging 2005, 26:475-484.
35. Kantarci K., Lowe V., Przybelski S.A., Weigand S.D., Senjem M.L., Ivnik R.J., Perboske G.M., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 2012, 78:232-240.
36. Kline, R.B., 2011., Principles and Practice of Structural Equation Modeling, third ed. Guilford, New York.
37. Komulainen P., Pedersen M., Hanninen T., Bruunsgaard H., Lakka T.A., Kivipelto M., Hassinen M., Rauramaa T.H., Pedersen B.K., Rauramaa R. BDNF is a novel marker of cognitive function ageing women: the DR's EXTRA study. Neurobiol. Learn. Mem. 2008, 90:596-603.
38. Lindenberger U., Nagel I.E., Chicherio C., Li S., Heekeren H.R., Bäckman L. Age-related decline in brain resources modulates genetic effects on cognitive functioning. Front. Neurosci. 2008, 2:234-243.
39. Luszcz M.A. Executive function and cognitive aging. Handbook of the Psychology of Aging (seventh ed.) 2011, 59-72. Academic Press, San Diego. K.W. Schaie, S.L. Willis (Eds.).
40. MacDonald S.W.S., Dixon R.A., Cohen A.-L., Hazlitt J.E. Biological age and 12-year cognitive change in older adults: findings from the Victoria Longitudinal Study. Gerontology 2004, 50:64-81.
41. MacDonald S.W.S., DeCarlo C.A., Dixon R.A. Linking biological and cognitive aging: towards improving characterizations of developmental time. J.Gerontol. B Psychol. Sci. Soc. Sci. 2011, 66:i59-i70.
42. Mandelman S.D., Grigorenko E.L. BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav. 2012, 11:127-136.
43. McClearn G.E. Contextual genetics. Trends Genet. 2006, 22:314-319.
44. McFall G.M., Wiebe S.A., Vergote D., Jhamandas J., Westaway D., Dixon R.A. IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults. Psychol. Aging 2014, 29:418-430.
45. McFall G.M., Wiebe S.A., Vergote D., Westaway D., Jhamandas J., Dixon R.A. IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults. Neurobiol. Aging 2013, 34:2208-2216.
46. McIntosh A.M., Gow A., Luciano M., Davies G., Liewald D.C., Harris S.E., Corely J., Hall J., Starr J.M., Porteous D.J., Tenesa A., Visscher P.M., Deary I.J. Polygenic risk for schizophrenia is associated with cognitive change between childhood and old age. Biol. Psychiatry 2013, 73:938-943.
47. Miyajima F., Quinn J.P., Horan M., Pickles A., Ollier W.E., Pendleton N., Payton A. Additive effect of BDNF and REST polymorphisms is associated with improved general cognitive ability. Genes Brain Behav. 2008, 7:714-719.
48. Muthén, L.K., Muthén, B.O., 1998-2012. Mplus User's Guide, seventh ed. Muthén and Muthén, Los Angeles.
49. Nagel I.E., Chicherio C., Li S., Oertzen T., Sander T., Villringer A., Heekeren H.R., Bäckman L., Lindenberger U. Human aging magnifies genetic effects on executive functioning and working memory. Front. Hum. Neurosci. 2008, 2:1-6.
50. Nakamura E., Miyao K. Amethod for identifying biomarkers of aging and constructing an index of biological age in humans. J.Geront A Biol. Sci. Med. Sci. 2007, 62:1096-1105.
51. Niti M., Yap K.B., Eua E.H., Tan C.H., Ng T.P. Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int. Psychogeriatr. 2008, 20:237-251.
52. Panza F., Solfrizzi V., Torres F., Mastroianni F., Colacicco A.M., Basile A.M., Capurso C., D'Introno A., Del Parigi A., Capurso A. Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early-and late-onset sporadic Alzheimer's disease. Neurosci. Lett. 2000, 292:79-82.
53. Payton A. The impact of genetic research on our understanding of normal cognitive aging: 1995-2009. Neuropsychol. Rev. 2009, 19:451-477.
54. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752. International Schizophrenia Consortium.
55. Raz N., Rodriguez K.M., Kennedy K.M., Land S. Genetic and vascular modifiers of age-sensitive cognitive skills: effects of COMT, BDNF, ApoE, and hypertension. Neuropsychology 2009, 23:105-116.
56. Risacher S.L., Kim S., Shen L., Nho K., Foroud T., Green R.C., Petersen R.C., Jack C.R., Aisen P.S., Koeppe R.A., Jagust W.J., Shaw L.M., Trojanowski J.Q., Weiner M.W., Saykin A.J. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front. Aging Neurosci. 2013, 5:11. Alzheimer's Disease Neuroimaging Initiative (ADNI).
57. Saunders M., Strittmatter W.J., Schmechel D., St.George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crappers-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993, 43:1467-1472.
58. Savitz J., Solms M., Ramesar R. The molecular genetics of cognition: dopamine, COMT and BDNF. Genes Brain Behav. 2006, 5:311-328.
59. Seaquist E.R., Lattemann D.F., Dixon R.A. American diabetes association research symposium: diabetes and the brain. Diabetes 2012, 61:3056-3062.
60. Small B.J., Rosnick C.B., Fratiglioni L., Bäckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol. Aging 2004, 19:592-600.
61. Starr J.M., Fox H., Harris S.E., Deary I.J., Whalley L.J. COMT genotype and cognitive ability: a longitudinal aging study. Neurosci. Lett. 2007, 421:57-61.
62. Verghese P.B., Castellano J.M., Holtzman D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol. 2011, 10:241-252.
63. Verhaaren B.F.J., Vernooji M.W., Koudstaal P.J., Uitterlinden A.G., van Duijn C.M., Hofman A., Breteler M.M., Ikram M.A. Alzheimer's disease genes and cognition in the nondemented general population. Biol. Psychiatry 2013, 73:429-434.
64. Wisdom N.M., Callahan J.L., Hawkins K.A. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol. Aging 2011, 32:63-74.
65. Wishart H.A., Roth R.M., Saykin A.J., Rhodes C.H., Tsongalis G.J., Pattin K.A., Moore J.H., McAllister T.W. COMT Val158Met genotype and individual differences inexecutive function in healthy adults. J.Int. Neuropsychol. Soc. 2011, 17:174-178.
66. Woodard J.L., Sugarman M.A., Nielson K.A., Smith J.C., Seidenberg M., Durgerian S., Butts A., Hantke N., Lancaster M., Matthews M.A., Rao S.M. Lifestyle and genetic contributions to cognitive decline and hippocampal structure and function in healthy aging. Curr. Alzheimer Res. 2012, 9:436-446.